Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a conference ...

The presentation slides and a link to the live and archived webcast will also be available on the Events & News – Events page of Jasper's Investor Relations website.

Macrilen ® (macimorelin), COSCIENS’ lead pharmaceutical product, is a ghrelin agonist that stimulates the secretion of growth hormone from the pituitary gland and is the first and only U.S. Food and ...

According to IQVIA ® U.S. annual sales for cyclosporine ophthalmic emulsion 0.05% in sterile, preservative-free single-use vials for the 12 months ended September 2025 were approximately $2.0 billion.

PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer ...

Belite Bio intends to use the net proceeds of the offering for (i) commercialization preparation, including building our in-house commercialization team, establishing sales network and systems, and ...

Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer ...

Under Nasdaq rules, the Company now has 60 calendar days to submit a plan to regain compliance and if such plan is accepted by Nasdaq, an exception of up to 180 calendar days from the original ...

Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has been selected for an oral presentation of ...

The above-described award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635 (c) (4) and was granted pursuant ...

Under the program, Regional may purchase shares of the Company’s Series B Preferred Stock from time to time through open-market and privately negotiated transactions, through block trades, and ...

Vlad Vitoc, M.D., Chairman and CEO of MAIA, purchased 94,300 shares between November 21 and 28, 2025, at an average price of $1.08 per share. Other board members, Cristian Luput and Stan V. Smith, ...